Effects of once-daily teneligliptin on 24-h blood glucose control and safety in Japanese patients with type 2 diabetes mellitus: a 4-week, randomized, double-blind, placebo-controlled trial-Reference-Cited by-同舟云学术

Effects of once-daily teneligliptin on 24-h blood glucose control and safety in Japanese patients with type 2 diabetes mellitus: a 4-week, randomized, double-blind, placebo-controlled trial

Published:2012-07-29 Issue:11 Volume:14 Page:1040-1046
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Eto T.¹,Inoue S.²,Kadowaki T.³

Affiliation:

1. Internal Medicine; Medical Co. LTA PS Clinic; Fukuoka; Japan

2. Heishinkai Medical Group Incorporated OCROM Clinic; Osaka; Japan

3. Department of Metabolic Diseases; Graduate School of Medicine, The University of Tokyo; Tokyo; Japan

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1463-1326.2012.01662.x/fullpdf

Reference10 articles.

1. Glucagon-like peptide-1 7-36: a physiological incretin in man;Kreymann;Lancet,1987

2. Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39;Edwards;Diabetes,1999

3. Protein kinase Czeta activation mediates glucagon-like peptide-1-induced pancreatic beta-cell proliferation;Buteau;Diabetes,2001

4. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats;Xu;Diabetes,1999

5. Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man;Wettergren;Dig Dis Sci,1993

Cited by 68 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Effect of Vitamin D Supplementation on Glycemic Control and Cardiovascular Risk Factors in Type 2 Diabetes: An Updated Systematic Review and Meta‐Analysis of Clinical Trials;Journal of Diabetes Research;2024-01

2. Evaluation of Age-Related Changes in Teneligliptin Pharmacokinetics in Japanese and European Descent Subjects Using a Physiologically Based Pharmacokinetic Model;Diabetes Therapy;2023-12-20

3. A model‐informed approach to accelerate the clinical development of cofrogliptin (HSK7653), a novel ultralong‐acting dipeptidyl peptidase‐4 inhibitor;Diabetes, Obesity and Metabolism;2023-11-12

4. A Critical View over the Newest Antidiabetic Molecules in Light of Efficacy—A Systematic Review and Meta-Analysis;International Journal of Molecular Sciences;2023-06-05

5. Potential approaches using teneligliptin for the treatment of type 2 diabetes mellitus: current status and future prospects;Expert Review of Clinical Pharmacology;2023-01-02